Ginaton
Phase 2Small molecule
Ginaton is one of 100 small molecule programs targeting Hearing Loss. It is currently in Phase 2.
3
Indications
4
Total Trials
2
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Ginaton
PPeking University People's Hospital
Phase 2
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statins
SanofiPreclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ginkgo Biloba Extract
NNational Center for Complementary and Integrative Health (NCCIH)
Preclinical
Aspirin or Clopidogrel
SSunnybrook Health Sciences Centre
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ISS1 trial
The Effect of PAP on ISSHL Comorbided With OSA
Recruiting·—·Phase 4·NCT04192656·102 enrolled
Ischemic stroke1 trial
Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke
Completed·—·N/A·NCT05169450·998 enrolled
Diabetic Retinopathy1 trial
Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07236645·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ginaton. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details